Selected treatment regimens for patients with WM
| Study . | Agent . | N (TN/RR) . | ORR, % . | MRR, % . | VGPR, % . | PFS . | Adverse events . |
|---|---|---|---|---|---|---|---|
| Dimopoulos et al44 | Cyclophosphamide, D, R | 72 (72/0) | 83 | 74 | 7 | Median: 35 mo | Cytopenias, infections, myeloid neoplasms |
| Rummel et al45 | Bendamustine, R | 19 (19/0) | NR | NR | NR | Median: 69.5 mo | |
| R-CHOP | 22 (22/0) | NR | NR | NR | Median: 28 mo | ||
| Rummel et al27 | Bendamustine, R | 257 (257/0) | 92 | 88 | 4 | Median: 65 mo | |
| Treon et al22 | Bortezomib (twice weekly), D, R | 23 (23/0) | 96 | 83 | 22 | Median: 66 mo | Neuropathy, neutropenia, infections |
| Dimopoulos et al46 | Bortezomib (weekly), D, R | 59 (59/0) | 85 | 58 | 10 | Median: 42 mo | |
| Treon et al47 | Carfilzomib, D, R | 31 (31/0) | 87 | 68 | 35 | Median: 44 mo | Hyperglycemia, hyperlipasemia |
| Castillo et al48 | Ixazomib, D, R | 26 (26/0) | 96 | 77 | 15 | Median: NR at 22 mo | Infections, hyperglycemia |
| Treon et al28,29 | Ibrutinib | 63 (0/63) | 91 | 81 | 16 | 5 y: 54% | Cytopenias, bleeding, arrhythmias, hypertension |
| Treon et al36 | Ibrutinib | 30 (30/0) | 100 | 83 | 20 | 18 mo: 92% | |
| Dimopoulos et al34 | Ibrutinib, R | 75 (34/41) | 93 | 73 | 26 | 30 mo: 82% | |
| Owen et al37 | Acalabrutinib | 106 (14/92) | 93 | 78 | 8 (IWWM6) 29 (IWWM3) | 24 mo: 90% (TN); 82% (RR) |
| Study . | Agent . | N (TN/RR) . | ORR, % . | MRR, % . | VGPR, % . | PFS . | Adverse events . |
|---|---|---|---|---|---|---|---|
| Dimopoulos et al44 | Cyclophosphamide, D, R | 72 (72/0) | 83 | 74 | 7 | Median: 35 mo | Cytopenias, infections, myeloid neoplasms |
| Rummel et al45 | Bendamustine, R | 19 (19/0) | NR | NR | NR | Median: 69.5 mo | |
| R-CHOP | 22 (22/0) | NR | NR | NR | Median: 28 mo | ||
| Rummel et al27 | Bendamustine, R | 257 (257/0) | 92 | 88 | 4 | Median: 65 mo | |
| Treon et al22 | Bortezomib (twice weekly), D, R | 23 (23/0) | 96 | 83 | 22 | Median: 66 mo | Neuropathy, neutropenia, infections |
| Dimopoulos et al46 | Bortezomib (weekly), D, R | 59 (59/0) | 85 | 58 | 10 | Median: 42 mo | |
| Treon et al47 | Carfilzomib, D, R | 31 (31/0) | 87 | 68 | 35 | Median: 44 mo | Hyperglycemia, hyperlipasemia |
| Castillo et al48 | Ixazomib, D, R | 26 (26/0) | 96 | 77 | 15 | Median: NR at 22 mo | Infections, hyperglycemia |
| Treon et al28,29 | Ibrutinib | 63 (0/63) | 91 | 81 | 16 | 5 y: 54% | Cytopenias, bleeding, arrhythmias, hypertension |
| Treon et al36 | Ibrutinib | 30 (30/0) | 100 | 83 | 20 | 18 mo: 92% | |
| Dimopoulos et al34 | Ibrutinib, R | 75 (34/41) | 93 | 73 | 26 | 30 mo: 82% | |
| Owen et al37 | Acalabrutinib | 106 (14/92) | 93 | 78 | 8 (IWWM6) 29 (IWWM3) | 24 mo: 90% (TN); 82% (RR) |
D, dexamethasone; MRR, major response rate; NR, not reported; R, rituximab; R-CHOP, rituximab, cyclophosphamide, doxorubucin, vincristine, and prednisone; RR, relapsed/refractory; TN, treatment naive.